Uncoupling the widespread occurrence of anti-NMDAR1 autoantibodies from neuropsychiatric disease in a novel autoimmune model.

Adult Animals Anti-N-Methyl-D-Aspartate Receptor Encephalitis / immunology Autoantibodies / immunology Blood-Brain Barrier Brain / immunology Cats Dogs Female Humans Immunoglobulin G / genetics Male Mental Disorders / immunology Mice Nerve Tissue Proteins / immunology Neurons / immunology Primates Rats Receptors, N-Methyl-D-Aspartate / immunology Seroepidemiologic Studies

Journal

Molecular psychiatry

ISSN: 1476-5578

Titre abrégé: Mol Psychiatry

Pays: England

ID NLM: 9607835

Informations de publication

Date de publication:
10 2019

Historique:

received: 29 08 2017

accepted: 30 10 2017

revised: 20 10 2017

pubmed: 11 2 2018

medline: 22 5 2020

entrez: 11 2 2018

Statut: ppublish

Résumé

Autoantibodies of the IgG class against N-methyl-D-aspartate-receptor subunit-NR1 (NMDAR1-AB) were considered pathognomonic for anti-NMDAR encephalitis. This view has been challenged by the age-dependent seroprevalence (up to >20%) of functional NMDAR1-AB of all immunoglobulin classes found in >5000 individuals, healthy or affected by different diseases. These findings question a merely encephalitogenic role of NMDAR1-AB. Here, we show that NMDAR1-AB belong to the normal autoimmune repertoire of dogs, cats, rats, mice, baboons, and rhesus macaques, and are functional in the NMDAR1 internalization assay based on human IPSC-derived cortical neurons. The age dependence of seroprevalence is lost in nonhuman primates in captivity and in human migrants, raising the intriguing possibility that chronic life stress may be related to NMDAR1-AB formation, predominantly of the IgA class. Active immunization of ApoE

Identifiants

DOI: 10.1038/s41380-017-0011-3 PMID: 29426955 PMC: PMC6756099

pubmed: 29426955

doi: 10.1038/s41380-017-0011-3

pii: 10.1038/s41380-017-0011-3

pmc: PMC6756099

doi:

Substances chimiques

Autoantibodies 0

GRIN1 protein, human 0

Immunoglobulin G 0

NMDA receptor A1 0

Nerve Tissue Proteins 0

Receptors, N-Methyl-D-Aspartate 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

1489-1501

Références

Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61:25–36.

doi: 10.1002/ana.21050

Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091–8.

doi: 10.1016/S1474-4422(08)70224-2

Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63–74.

doi: 10.1016/S1474-4422(10)70253-2

Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–65.

doi: 10.1016/S1474-4422(12)70310-1

Hammer C, Stepniak B, Schneider A, Papiol S, Tantra M, Begemann M, et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol Psychiatry. 2014;19:1143–9.

doi: 10.1038/mp.2013.110

Dahm L, Ott C, Steiner J, Stepniak B, Teegen B, Saschenbrecker S, et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol. 2014;76:82–94.

doi: 10.1002/ana.24189

Steiner J, Teegen B, Schiltz K, Bernstein HG, Stoecker W, Bogerts B. Prevalence of N-methyl-D-aspartate receptor autoantibodies in the peripheral blood: healthy control samples revisited. JAMA Psychiatry. 2014;71:838–9.

doi: 10.1001/jamapsychiatry.2014.469

Zerche M, Weissenborn K, Ott C, Dere E, Asif AR, Worthmann H, et al. Preexisting serum autoantibodies against the NMDAR subunit NR1 modulate evolution of lesion size in acute ischemic stroke. Stroke. 2015;46:1180–6.

doi: 10.1161/STROKEAHA.114.008323

Castillo-Gomez E, Kastner A, Steiner J, Schneider A, Hettling B, Poggi G, et al. The brain as immunoprecipitator of serum autoantibodies against N-Methyl-D-aspartate receptor subunit NR1. Ann Neurol. 2016;79:144–51.

doi: 10.1002/ana.24545

Castillo-Gomez E, Oliveira B, Tapken D, Bertrand S, Klein-Schmidt C, Pan H et al. All naturally occurring autoantibodies against the NMDA receptor subunit NR1 have pathogenic potential irrespective of epitope and immunoglobulin class. Mol Psychiatry. 2016;22:1776–178.

doi: 10.1038/mp.2016.125

Abramson J, Husebye ES. Autoimmune regulator and self-tolerance—molecular and clinical aspects. Immunol Rev. 2016;271:127–40.

doi: 10.1111/imr.12419

Cohen I, Young D. Autoimmunity, microbial immunity and the immunological homunculus. Immunol Today. 1991;12:105–10.

doi: 10.1016/0167-5699(91)90093-9

Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol. 1995;7:812–8.

doi: 10.1016/0952-7915(95)80053-0

Ehrenreich H. Autoantibodies against the N-methyl-d-aspartate receptor subunit NR1: untangling apparent inconsistencies for clinical practice. Front Immunol. 2017;8:181.

doi: 10.3389/fimmu.2017.00181

Lobo PI. Role of natural autoantibodies and natural IgM anti-leucocyte autoantibodies in health and disease. Front Immunol. 2016;7:198.

doi: 10.3389/fimmu.2016.00198

Mader S, Brimberg L, Diamond B. The role of brain-reactive autoantibodies in brain pathology and cognitive impairment. Front Immunol. 2017;8:1101.

doi: 10.3389/fimmu.2017.01101

Nguyen TT, Baumgarth N. Natural IgM and the development of b cell-mediated autoimmune diseases. Crit Rev Immunol. 2016;36:163–77.

doi: 10.1615/CritRevImmunol.2016018175

Coutinho E, Harrison P, Vincent A. Do neuronal autoantibodies cause psychosis? A neuroimmunological perspective. Biol Psychiatry. 2014;75:269–75.

doi: 10.1016/j.biopsych.2013.07.040

Diamond B, Huerta P, Mina-Osorio P, Kowal C, Volpe B. Losing your nerves? Maybe it’s the antibodies. Nat Rev Immunol. 2009;9:449–56.

doi: 10.1038/nri2529

Hammer C, Zerche M, Schneider A, Begemann M, Nave KA, Ehrenreich H. Apolipoprotein E4 carrier status plus circulating anti-NMDAR1 autoantibodies: association with schizoaffective disorder. Mol Psychiatry. 2014;19:1054–6.

doi: 10.1038/mp.2014.52

Kreye J, Wenke NK, Chayka M, Leubner J, Murugan R, Maier N, et al. Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis. Brain. 2016;139:2641–52.

doi: 10.1093/brain/aww208

Begemann MGS, Papiol S, Malzahn D, Krampe H, Ribbe K, et al. Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms. Arch Gen Psychiatry. 2010;67:879–88.

doi: 10.1001/archgenpsychiatry.2010.107

Ribbe. K, Friedrichs H, Begemann M, Grube S, Papiol S, Kästner. A, et al. The cross-sectional GRAS sample: a comprehensive phenotypical data collection of schizophrenic patients. BMC Psychiatry. 2010;10:0–20.

doi: 10.1186/1471-244X-10-91

American Psychiatric Association. (2000) Diagnostic and statistical manual of mental disorders. 4th edn American Psychiatric Press, Washington, DC. .

Wandinger KP, Saschenbrecker S, Stoecker W, Dalmau J. Anti-NMDA-receptor encephalitis: a severe, multistage, treafa disorder presenting with psychosis. J Neuroimmunol. 2011;231:86–91.

doi: 10.1016/j.jneuroim.2010.09.012

Boyle MDP, Reis KJ. Bacterial Fc receptors. Nat Biotechnol. 1987;5:697–703.

doi: 10.1038/nbt0787-697

Pruss H, Leubner J, Wenke NK, Czirjak GA, Szentiks CA, Greenwood AD. Anti-NMDA receptor encephalitis in the polar bear (Ursus maritimus) Knut. Sci Rep. 2015;5:1–7.

doi: 10.1038/srep12805

Toyka KBD, Pestronk A, Kao I. Myasthenia gravis: passive transfer from man to mouse. Science. 1975;190:397–9.

doi: 10.1126/science.1179220

Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676–82.

doi: 10.1038/nmeth.2019

Berghoff SA, Gerndt N, Winchenbach J, Stumpf SK, Hosang L, Odoardi F, et al. Dietary cholesterol promotes repair of demyelinated lesions in the adult brain. Nat Commun. 2017;8:1–15.

doi: 10.1038/ncomms14241

Berghoff SA, Düking T, Spieth L, Winchenbach J, Stumpf SK, Gerndt N, et al. Blood-brain barrier hyperpermeability precedes demyelination in the cuprizone model. Acta Neuropathol Commun. 2017;5:94.

doi: 10.1186/s40478-017-0497-6

Wust S, van den Brandt J, Tischner D, Kleiman A, Tuckermann JP, Gold R, et al. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J Immunol. 2008;180:8434–43.

doi: 10.4049/jimmunol.180.12.8434

Dere E, Dahm L, Lu D, Hammerschmidt K, Ju A, Tantra M, et al. Heterozygous ambra1 deficiency in mice: a genetic trait with autism-like behavior restricted to the female gender. Front Behav Neurosci. 2014;8:181.

pubmed: 24904333 pmcid: 4032889

Dere E, Winkler D, Ritter C, Ronnenberg A, Poggi G, Patzig J, et al. Gpm6b deficiency impairs sensorimotor gating and modulates the behavioral response to a 5-HT2A/C receptor agonist. Behav Brain Res. 2015;277:254–63.

doi: 10.1016/j.bbr.2014.04.021

Netrakanti PR, Cooper BH, Dere E, Poggi G, Winkler D, Brose N, et al. Fast cerebellar reflex circuitry requires synaptic vesicle priming by munc13-3. Cerebellum. 2015;14:264–83.

doi: 10.1007/s12311-015-0645-0

Winkler D, Daher F, Wustefeld L, Hammerschmidt K, Poggi G, Seelbach A et al. Hypersocial behavior and biological redundancy in mice with reduced expression of PSD95 or PSD93. Behav Brain Res. 2017. https://doi.org/10.1016/j.bbr.2017.02.011 (e-pub ahead of print).

doi: 10.1016/j.bbr.2017.02.011

Radyushkin K, El-Kordi A, Boretius S, Castaneda S, Ronnenberg A, Reim K, et al. Complexin2 null mutation requires a ‘second hit’ for induction of phenotypic changes relevant to schizophrenia. Genes Brain Behav. 2010;9:592–602.

pubmed: 20412316

Akdeniz C, Tost H, Streit F, Haddad L, Wust S, Schafer A, et al. Neuroimaging evidence for a role of neural social stress processing in ethnic minority-associated environmental risk. JAMA Psychiatry. 2014;71:672–80.

doi: 10.1001/jamapsychiatry.2014.35

Jacobson SL, Ross SR, Bloomsmith MA. Characterizing abnormal behavior in a large population of zoo-housed chimpanzees: prevalence and potential influencing factors. PeerJ. 2016;4:e2225.

doi: 10.7717/peerj.2225

Stepniak B, Papiol S, Hammer C, Ramin A, Everts S, Hennig L, et al. Accumulated environmental risk determining age at schizophrenia onset: a deep phenotyping-based study. Lancet Psychiatry. 2014;1:444–53.

doi: 10.1016/S2215-0366(14)70379-7

Maes M, Hendriks D, Gastel AV, Demedts P, Wauters A, Neels H, et al. Effects of psychological stress on serum immunoglobulin, complement and acute phase protein concentrationsin normal volunteers. Psychoneuroendocrinology. 1997;2:397–409.

doi: 10.1016/S0306-4530(97)00042-5

Nagele EP, Han M, Acharya NK, DeMarshall C, Kosciuk MC, Nagele RG. Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS ONE. 2013;8:4.

doi: 10.1371/journal.pone.0060726

Planaguma J, Leypoldt F, Mannara F, Gutierrez-Cuesta J, Martin-Garcia E, Aguilar E, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain. 2015;138:94–109.

doi: 10.1093/brain/awu310

Busse S, Brix B, Kunschmann R, Bogerts B, Stoecker W, Busse M. N-methyl-d-aspartate glutamate receptor (NMDA-R) antibodies in mild cognitive impairment and dementias. Neurosci Res. 2014;85:58–64.

doi: 10.1016/j.neures.2014.06.002

Doss S, Wandinger KP, Hyman BT, Panzer JA, Synofzik M, Dickerson B, et al. High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types. Ann Clin Transl Neurol. 2014;1:822–32.

doi: 10.1002/acn3.120

Tuzun E, Zhou L, Baehring JM, Bannykh S, Rosenfeld MR, Dalmau J. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol. 2009;118:737–43.

doi: 10.1007/s00401-009-0582-4

Du J, Li XH, Li YJ. Glutamate in peripheral organs: biology and pharmacology. Eur J Pharmacol. 2016;784:42–8.

doi: 10.1016/j.ejphar.2016.05.009

Gerhard DM, Wohleb ES, Duman RS. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. Drug Discov Today. 2016;21:454–64.

doi: 10.1016/j.drudis.2016.01.016

Abdallah CG, Adams TG, Kelmendi B, Esterlis I, Sanacora G, Krystal JH. Ketamine’s mechanism of action: a path to rapid-acting antidepressants. Depress Anxiety. 2016;33:689–97.

doi: 10.1002/da.22501

Alexander JK, DeVries AC, Kigerl KA, Dahlman JM, Popovich PG. Stress exacerbates neuropathic pain via glucocorticoid and NMDA receptor activation. Brain Behav Immun. 2009;23:851–60.

doi: 10.1016/j.bbi.2009.04.001

Rubio-Casillas A, Fernandez-Guasti A. The dose makes the poison: from glutamate-mediated neurogenesis to neuronal atrophy and depression. Rev Neurosci. 2016;27:599–622.

doi: 10.1515/revneuro-2015-0066

Nair A, Hunzeker J, Bonneau RH. Modulation of microglia and CD8(+) T cell activation during the development of stress-induced herpes simplex virus type-1 encephalitis. Brain Behav Immun. 2007;21:791–806.

doi: 10.1016/j.bbi.2007.01.005